$TCMD

Dodd Sheri Louise sold $323K of TCMD

Dodd Sheri Louise (Chief Executive Officer) sold 10,978 shares of TACTILE SYSTEMS TECHNOLOGY INC (TCMD) at $29.44 ($0.32M total) on 2026-08-10.

Original reporting
SEC EDGAR · Dodd Sheri Louise
Published Aug 12, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TCMD
Neutral
medium confidence
Mentioned
$TCMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TCMDNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value, and post-transaction holdings). This can slightly influence sentiment but does not provide new operational or financial information.

02

Market read

A newly filed insider sale can create minor near-term sentiment noise, but it is typically not a standalone trading catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or financing, the signal is usually weak. Watch for subsequent insider activity or material filings.

Relevance 4/10Novelty 4/10Timing: filed Aug 12, transaction dated Aug 10 (after-hours disclosure window)

Background

The article is a SEC Form 4 insider transaction disclosure for Tactile Systems Technology Inc (TCMD).

Company-level read

Ticker impact

$TCMDNeutralMedium confidence
Context

TCMD CEO Dodd Sheri Louise sold 10,978 shares in an open-market transaction for about $323,243, per a newly filed Form 4.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but it does not include new company performance, guidance, or regulatory/legal developments.

Market effects

No sector-level implications; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply negative information; sales can be driven by diversification, taxes, or pre-planned personal liquidity needs.

Key entities

  • TCMD

    Tactile Systems Technology Inc, the company whose CEO insider sale is disclosed.

  • Dodd Sheri Louise

    Chief Executive Officer and director who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TCMDMedAI 8/10

Tactile Systems Technology (TCMD) Q2 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) reported Q2 2026 revenue of $85.7M, up 9% Y/Y, driven by lymphedema revenue of $73.6M (+12%). Airway clearance revenue fell 7% to $12.1M due to distributor inventory dynamics. Gross margin was 76.3%. Adjusted EBITDA rose to $11.4M (+49%). FY2026 revenue guidance was set at $360M-$366M and EBITDA at $49M-$51M.

$TCMDMed

Tactile Systems Technology, Inc. Q2 2026 Earnings Call Summary

Tactile Systems Technology reported Q2 2026 results: lymphedema revenue rose 12% YoY on Flexitouch adoption, while airway clearance revenue fell 7% as large DME partners paused orders amid elevated inventory. Gross margin increased 180 bps to 76.3%. Full-year 2026 revenue guidance was raised to $360m-$366m; MyoSleeve launch and LymphaTech FDA submission are ongoing.

$TCMDHigh

Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with ch

$TCMDMedAI 8/10

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.